FREQUENTLY ASKED QUESTIONS

DUPIXENT is the first and only treatment for EoE patients as young as 1 year old, weighing at least 15 kg. DUPIXENT is a biologic that inhibits IL-4 and IL-13 signaling, two of the key drivers of type 2 inflammation contributing to EoE. DUPIXENT is not an immunosuppressant. The mechanism of dupilumab action has not been definitively established.¹

EXPLORE THE MECHANISM
OF ACTION

DUPIXENT is not a steroid or an immunosuppressant. DUPIXENT is a biologic that inhibits IL-4 and IL-13 signaling, two of the key drivers of type 2 inflammation contributing to EoE. The mechanism of dupilumab action has not been definitively established.¹

EXPLORE THE
mechanism OF ACTION

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).¹

View the Efficacy Data for Pediatric Patients

In addition to EoE, DUPIXENT is also indicated in 8 additional conditions driven in part by type 2 inflammation: uncontrolled moderate-to-severe atopic dermatitis (6+ months of age), uncontrolled moderate-to-severe eosinophilic or OCS-dependent asthma (6+ years of age [Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus]), inadequately controlled chronic rhinosinusitis with nasal polyps (12+ years of age), prurigo nodularis (18+ years of age), inadequately controlled chronic obstructive pulmonary disease with an eosinophilic phenotype (18+ years of age [Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm]), chronic spontaneous urticaria (patients 12+ years of age who remain symptomatic despite H1 antihistamine treatment [Limitations of Use: DUPIXENT is not indicated for treatment of other forms of urticaria]), bullous pemphigoid (18+ years of age), and allergic fungal rhinosinusitis (patients 6+ years of age with a history of sino-nasal surgery).¹

LEARN MORE

The efficacy and safety of DUPIXENT were evaluated for up to 52 weeks in two multipart, phase 3 clinical trials.^1,2

View the study design in adults & adolescents, 12+ years

View the study design in children, 1-11 years

What did the clinical results for DUPIXENT show?

What were the results of DUPIXENT on histologic findings?

Want to see the impact DUPIXENT had on the endoscopic features?

What were the safety results of DUPIXENT in EoE clinical trials?

DUPIXENT does NOT have any known drug-to-drug interactions. DUPIXENT is NOT metabolized through the liver or excreted
through the kidneys.¹

There is no requirement for initial lab testing or ongoing lab monitoring with DUPIXENT according to the Prescribing Information.¹

SEE PRESCRIBING
INFORMATION

Want to learn about the dosing and administration for DUPIXENT?

See how to administer

Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT. It is unknown if administration of live vaccines during DUPIXENT treatment will impact the safety or effectiveness of these vaccines. Limited data are available regarding coadministration of DUPIXENT with non-live vaccines.¹

LEARN MORE ABOUT DOSING AND ADMINISTRATION

No. Tuberculosis testing is not required with DUPIXENT according to the Prescribing Information.¹